High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison.
暂无分享,去创建一个
Keiichi Nakagawa | Masao Tago | T. Todo | Y. Ino | K. Nakagawa | Minoru Tanaka | Tomoki Todo | Yasushi Ino | Minoru Tanaka | M. Tago
[1] W. Curran,et al. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. , 2000, International Journal of Radiation Oncology, Biology, Physics.
[2] Susan M. Chang,et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[3] W. Powlis,et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. , 1993, International journal of radiation oncology, biology, physics.
[4] M. Martel,et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. , 1999, International journal of radiation oncology, biology, physics.
[5] P. Rubin,et al. High dose radiation therapy in the treatment of malignant gliomas: final report. , 1979, International journal of radiation oncology, biology, physics.
[6] F. Mornex,et al. Radiation therapy for malignant astrocytomas in adults. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] E. B. Butler,et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. , 2004, International journal of radiation oncology, biology, physics.
[8] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[9] Christopher Nimsky,et al. Proton Magnetic Resonance Spectroscopic Imaging Integrated into Image-guided Surgery: Correlation to Standard Magnetic Resonance Imaging and Tumor Cell Density , 2005, Neurosurgery.
[10] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[11] M. Prados,et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] D. Misailidou,et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Nelson,et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose‐escalation trial for malignant glioma (radiation therapy oncology group 83‐02) , 1994, Cancer.
[15] V. Strand,et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. , 2001, The Journal of rheumatology.
[16] A. Friedman,et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography , 1991, Annals of neurology.
[17] G. Pilkington,et al. Molecular and cellular pathology of intrinsic brain tumours , 1997, Cancer and Metastasis Reviews.
[18] Adam Dicker,et al. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. , 2004, International journal of radiation oncology, biology, physics.
[19] K. Nakagawa,et al. An integrated radiotherapy treatment system and its clinical application. , 1987, Radiation medicine.
[20] Maria Werner-Wasik,et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. , 2004, International journal of radiation oncology, biology, physics.
[21] J. O'fallon,et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Taenzer,et al. Acute Effects on Neuropsychological Function and Quality of Life by High‐Dose Multiple Daily Fractionated Radiotherapy for Malignant Astrocytomas: Assessing the Tolerability of a New Radiotherapy Regimen , 1997, Psycho-oncology.
[23] N. Laperriere,et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] K. Sultanem,et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. , 2004, International journal of radiation oncology, biology, physics.
[25] H. Bartelink,et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. , 1988, Frontiers of radiation therapy and oncology.
[26] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[27] D. Nelson,et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02 , 1996, Cancer.
[28] N. Bleehen,et al. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.
[29] M. Westphal,et al. Glioma invasion in the central nervous system. , 1996, Neurosurgery.
[30] K. Takakura,et al. Effects of ACNU and radiotherapy on malignant glioma. , 1986, Journal of neurosurgery.
[31] S. Piantadosi,et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Benedick A Fraass,et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Y. Katayama,et al. Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas , 2005, Journal of Neuro-Oncology.
[34] W. Simpson,et al. Fractionation study in the treatment of glioblastoma multiforme. , 1976, International journal of radiation oncology, biology, physics.
[35] K. Nakagawa,et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. , 1998, International journal of radiation oncology, biology, physics.
[36] M. Piérart,et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Walker,et al. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.
[38] P. Wen,et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. , 1999, Journal of neurosurgery.
[39] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.